Foco cáncer de pulmón y oncologÃa gastrointestinal
Foco cáncer de pulmón y oncologÃa gastrointestinal Foco cáncer de pulmón y oncologÃa gastrointestinal
E4599: unprecedented OS benefit in bevacizumab-‐treated pa2ents with adenocarcinoma histology • Bevacizumab-‐based therapy extends OS to 14.2 months OS es@mate 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 – increase of 3.9 months vs CP – 31% reduc2on in the risk of death HR (95% CI) CP (n=302) Bevacizumab 15mg/kg + CP (n=300) 0.69 (0.67–0.92) Median OS (months) 10.3 14.2 0.1 10.3 14.2 0 0 6 12 18 24 30 36 42 48 Dura@on of survival (months) Note: preplanned subgroup analysis in E4599 Sandler, et al. JTO 2008;3(Suppl. 4):S283 (Abs. 133)
Carbopla2no + Paclitaxel (PC) vs PC + Bevacizumab (BPC) – ECOG 4599 Variable PC BPC Toxicidad Neutropenia grado 4 (%) 0.7 4.4 Anemia (%) 0.9 0.9 Trombocitopenia (%) 0.2 1.6 Neutropenia febril (%) 1.8 4 Neutropenia febril grado 5 (%) 0.2 1.2 Hiponatremia (%) 1.1 3.5 Hipertensión grado 3 (%) 0.5 6.8 Hipertensión grado 4 (%) 0.2 0.2 Proteinuria grado 3 (%) - 2.6 Proteinuria grado 4 (%) - 0.5 Cefalea (%) 0.3 3 Exantema (%) 0.5 2.3 Sangrado grado 3-4 (%) 0.7 4.4 Sangrado grado 5 (%) 0.2 1.7 Sandler AG, Robert PMC, Brahmer J, et al. Paclitaxel-‐Carbopla@n Alone or with Bevacizumab for Non-‐Small-‐Cell Lung Cancer N Engl J Med 2006 355: 2542-‐2550
- Page 1 and 2: Protocolos de cáncer de pulmón -
- Page 3 and 4: Eficacia de los citotóxicos co
- Page 5 and 6: Cispla2no + Pemetrexed (CP) vs
- Page 7 and 8: NSCLC: Cisplatino + Pemetrexed Dosi
- Page 9 and 10: Forma de administrar Cisplatino - I
- Page 11 and 12: Cispla2no + Pemetrexed (CP) vs
- Page 13 and 14: Agentes dirigidos contra la ví
- Page 15 and 16: Carbopla2no + Paclitaxel (PC) v
- Page 17: Bevacizumab extends survival bey
- Page 21 and 22: Rejilla de decisión: NSCLC Ava
- Page 23 and 24: Atacando el EGFR: La familia H
- Page 25 and 26: Mok T, Wu YL, Thongprasert S,
- Page 27 and 28: Protocolos de cáncer de pulmón -
- Page 29 and 30: TAX320: overall survival Cumula2
- Page 31 and 32: JMEI: Eventos adversos AEs (grad
- Page 33 and 34: Erlo2nib showed overall survival
- Page 35 and 36: Protocolos de cáncer de pulmón -
- Page 37 and 38: Supervivencia (%) Observación Pign
- Page 39 and 40: SCLC: Cisplatino + Etopósido Dosis
- Page 41 and 42: Quimioterapia para tumores sólidos
- Page 43 and 44: Colon y recto: Mayo Dosis por metro
- Page 45 and 46: Colon y recto: XELOX (CAPOX) Dosis
- Page 47 and 48: Otros esquemas Cáncer de colon y
- Page 49 and 50: Cáncer de Recto
- Page 51 and 52: Quimioterapia para tumores pancreat
- Page 53 and 54: Vía biliar: Cisplatino + Gemcitabi
- Page 55 and 56: Carcinoma de cérvix uterino: Cispl
- Page 57 and 58: 50 Quimiorradiación concomitante
- Page 59 and 60: Proctitis Radiodermitis Vómito 2,8
- Page 61 and 62: Protocolos usuales de quimiotera
- Page 63 and 64: Protocolos usuales de quimiotera
E4599: unprece<strong>de</strong>nted OS benefit in bevacizumab-‐treated <br />
pa2ents with a<strong>de</strong>nocarcinoma histology <br />
• Bevacizumab-‐based therapy extends OS to 14.2 months <br />
OS es@mate <br />
1.0 <br />
0.9 <br />
0.8 <br />
0.7 <br />
0.6 <br />
0.5 <br />
0.4 <br />
0.3 <br />
0.2 <br />
– increase of 3.9 months vs CP <br />
– 31% reduc2on in the risk of <strong>de</strong>ath <br />
HR<br />
(95% CI)<br />
CP<br />
(n=302)<br />
Bevacizumab<br />
15mg/kg + CP<br />
(n=300)<br />
0.69<br />
(0.67–0.92)<br />
Median OS<br />
(months) 10.3 14.2<br />
0.1 <br />
10.3 14.2 <br />
0 <br />
0 6 12 18 24 30 36 42 48 <br />
Dura@on of survival (months) <br />
Note: preplanned subgroup <br />
analysis in E4599 <br />
Sandler, et al. JTO 2008;3(Suppl. 4):S283 (Abs. 133)
Change language